go to medicines.ie homepage
Font Size
Search for:  
select
  Advanced Search

Novartis Ireland Limited
Beech House, Beech Hill Office Campus, Clonskeagh, Dublin 4,
Telephone: +353 1 2601255
Fax: +353 1 2601263
Medical Information e-mail: medinfo.dublin@novartis.com
Summary of Product Characteristics last updated on medicines.ie: 14/03/2012
SPC Diovan 320mg Film coated tablets

When a pharmaceutical company changes an SPC or PIL, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 14/03/2012 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.4 - Special warnings and precautions for use
Date of revision of text on the SPC:   06-Mar-2012
Legal Category:   Product subject to medical prescription which may be renewed (B)

Free-text change information supplied by the pharmaceutical company
Section 4.4 Added in text:
"

History of angioedema

Angioedema, including swelling of the larynx and glottis, causing airway obstruction and/or swelling of the face, lips, pharynx, and/or tongue has been reported in patients treated with valsartan; some of these patients previously experienced angioedema with other drugs including ACE inhibitors. Diovan should be immediately discontinued in patients who develop angioedema, and Diovan should not be re-administered."
Updated on 13/04/2011 and displayed until 14/03/2012
Reasons for adding or updating:
  • Change to section 4.8 - Undesirable effects
  • Change to section 6.1 - List of excipients
Date of revision of text on the SPC:   03-Nov-2010
Legal Category:   Product subject to medical prescription which may be renewed (B)

Free-text change information supplied by the pharmaceutical company
Section 4.8 Added "Hyponatraemia" with frequency unknown.
Section 6.1 Updated excipient name of crospovidone to crospovidone Type A
Updated on 09/06/2010 and displayed until 13/04/2011
Reasons for adding or updating:
  • Change to section 3 - Pharmaceutical form
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 5.3 - Preclinical safety data
Date of revision of text on the SPC:   25-May-2010
Legal Category:   Product subject to medical prescription which may be renewed (B)

Free-text change information supplied by the pharmaceutical company
Sections 3, 6.4 and 6.5 were updated as a result of the Quality CMC harmonsiation procedure.
Section 4.1, 4.2, 4.4, 4.5, 4.6, 4.8, 5.1, 5.2 and 5.3 were all updated as a result of the new paediatric indication, taking into account the new Diovan 3mg/ml oral solution which has been introduced.
Updated on 30/06/2009 and displayed until 09/06/2010
Reasons for adding or updating:
  • Change to section 4.3 - Contraindications
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 5.3 - Preclinical safety data
Date of revision of text on the SPC:   28-Apr-2009
Legal Category:   Product subject to medical prescription which may be renewed (B)

Free-text change information supplied by the pharmaceutical company
All of the changes made to this SPC were as a result of the MRP Harmonisation procedure, i.e. bringing the SPC of countries who previously only had Diovan approved nationally inline with the SPC of all the current MRP countries, of which Ireland is one.  Therefore most of the changes were formatting and tidying up sections - the only main change for Ireland occured in section 4.3 and 4.6 relating to pregnancy which was previously contraindicated altogether, but now is only contraindicated for second and third trimesters.
Updated on 02/09/2008 and displayed until 30/06/2009
Reasons for adding or updating:
  • New SPC for new product

Document Links

 
  View all medicines
from this company
View Document
Bookmark and Share

Active Ingredients

 
  Valsartan